Fund moves
11.2MShares reported
4 tracked managers disclosed the same change for Q1 2025. From a 13F filed Aug 14, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 8, 2025 · Filed Aug 8, 2025
The CEO of Opko Health paid $891K out of pocket for Opko Health shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$891,000
Shares × reported transaction price
$500K–$1M
First purchase in 4 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 16 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 41% of the CEO's reported total pay for fiscal 2024 ($2.16M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-30. The proxy names Dr. Phillip Frost as CEO for that year. A size comparison, not a judgement
8 days after results of Jul 31, 2025, 82 days before results of Oct 29, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.7% | +1.2% | +6.5% |
| 30 days | +8.5% | +2.6% | +5.9% |
| 90 days | +2.3% | +7.2% | −4.8% |
| 180 days | −6.2% | +9.1% | −15.3% |
| 365 days | +6.9% | +21.2% | −14.3% |
Past results only. Not a forecast.
Fund moves
4 tracked managers disclosed the same change for Q1 2025. From a 13F filed Aug 14, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
4 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
4 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
FROST PHILLIP MD ET AL, CEO & Chairman's past purchases, 90 days after disclosure: 30 buys, median −2.2 pts vs S&P 500, beat it 13 of 30 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.